Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lurasidone - Sumitomo Dainippon Pharma

Drug Profile

Lurasidone - Sumitomo Dainippon Pharma

Alternative Names: DSP-1349M; Latuda; Lurasidone HCl; Lurasidone hydrochloride; Lurasidone injectable suspension; Lurasidone injection suspension; SM-13496; SMP-13496

Latest Information Update: 28 Jul 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Angelini Group; Bukwang Pharmaceutical; Daiichi Sankyo Company; DKSH Singapore; DKSH Thailand; Standard Chemical & Pharmaceutical Company; Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals; Takeda
  • Class Antidepressants; Antipsychotics; Cyclohexanes; Isoindoles; Piperazines; Small molecules; Thiazoles
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar depression; Schizophrenia
  • Preregistration Bipolar disorders
  • Phase III Autistic disorder; Major depressive disorder; Psychiatric disorders

Most Recent Events

  • 28 Jul 2021 No recent reports of development identified for phase-I development in Schizophrenia in USA (Parenteral, Suspension)
  • 25 May 2021 Sumitomo Pharmaceuticals announces intention to launch lurasidone for Bipolar depression in Japan in 2024 (Sumitomo Dainippon Pharma pipeline, May 2021)
  • 12 May 2021 Phase-III clinical trials in Schizophrenia (In children, In adolescents) in Japan (PO) before May 2021 (Sumitomo Dainippon Pharma's pipeline, May 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top